Cingulate

Cingulate Equity Ratio

The Equity Ratio of Cingulate (CING) as of Oct 21, 2026 is 16.64 %. In the previous year, Equity Ratio was 50.16 % — a change of -66.81% (lower).

Equity Ratio

16.64 %

YoY

-66.81%

Last updated:

Equity Ratio of Cingulate is 2025 16.64 % . Equity Ratio of Cingulate was 2024 50.16 % . It decreases by -66.81% lower compared to the previous year.

The Cingulate Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2019
11.66 USD
Jan 1, 2020
22.33 USD
Jan 1, 2021
91.07 USD
Jan 1, 2022
34.04 USD
Jan 1, 2023
-196.75 USD
Jan 1, 2024
50.16 USD
Jan 1, 2025
16.64 USD
The Cingulate Equity Ratio history
YEAREquity RatioYoY
16.64 %-66.81%
50.16 %-125.49%
-196.75 %-678.04%
34.04 %-62.63%
91.07 %+307.83%
22.33 %+91.48%
11.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Equity Ratio of Cingulate is 16.64 % in 2025.

Equity Ratio of Cingulate changed from 50.16 % to 16.64 %, representing a -66.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Cingulate since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Cingulate with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cingulate

All Key Metrics — Cingulate